Driving Development of Allogeneic Cell Therapies and CAR-T with Novel Signalling Technologies

Time: 6:00 pm
day: Day 1 – Track B – Evening


  • Leveraging naturally occurring multifunctional T-cell populations that harness innate and adaptive cell function
  • Developing non-gene edited allogeneic CAR-T therapies on a novel gamma-delta platform
  • Evolving platform capabilities using novel technologies for enhancement